7th Jul 2006 14:42
This correction relates to earlier release which displayed the incorrect dateSECOND QUARTER 2006 RESULTS DATE NOTIFICATION - July 28, 2006Basingstoke, UK and Philadelphia, US - 7 July 2006 - Shire plc (LSE: SHP,NASDAQ: SHPGY, TSX: SHQ) will announce second quarter 2006 earnings on Friday28 July 2006.Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT Live analyst presentation and conference call:Matthew Emmens, Chief Executive Officer and Angus Russell, Chief FinancialOfficer will host the investor and analyst meeting and live conference call at14:00 BST/9:00 EDT. The venue for the meeting will be at the offices ofFinancial Dynamics Offices, Holborn Gate, 26 Southampton Buildings, London WC2A1PBPlease RSVP [email protected] for the live presentation.Live conference call:The details of the live conference call are as follows:UK dial in 0800 953 0937 US / Canada dial in 1866 224 2914 / 1800 795 6202 International dial in + 44 (0)1452 569 103 Password/Conf ID 2802370 Please RSVP [email protected] for the conference callLive Webcast:The call will also be available live over the Internet via audio webcast,accessible through www.shire.com in the investor relations section. A slidepresentation to accompany the call will also be available on the Shire website.Replay:A replay of the presentation will be available for two weeks. Details are asfollows:UK dial in 0800 953 1533 International dial in +44 (0) 1452 55 00 00 Pin code 2802370 # Webcast replay www.shire.com, in the investor relations section If you have any problems accessing this, please contact: Souheil Salah on: +44(0) 1256 894160For further information please contact:Investor Relations Souheil Salah (Rest of the World) +44 1256 894 160 Heidi Wunder (North America) +1 484 595 8970 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on central nervous system, gastrointestinal, generalproducts and human genetic therapies. The structure is sufficiently flexible toallow Shire to target new therapeutic areas to the extent opportunities arisethrough acquisitions. Shire believes that a carefully selected portfolio ofproducts with a strategically aligned and relatively small-scale sales forcewill deliver strong results.Shire's focused strategy is to develop and market products for specialtyphysicians. Shire's in-licensing, merger and acquisition efforts are focused onproducts in niche markets with strong intellectual property protection eitherin the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com.ENDSHIRE PLCRelated Shares:
Shire